CLINICAL TRIALS PROFILE FOR VASOTEC

All Clinical Trials for VASOTEC

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01413542 ↗	Pharmacogenetics of Ace Inhibitor-Associated Angioedema	Completed	Vanderbilt University	N/A	2011-11-01	The investigators would like to find out if sitagliptin (dipeptidyl peptidase-4 or DPP4 inhibition), a drug to treat diabetes, affects blood vessel relaxation in healthy people receiving enalapril (angiotensin converting enzyme or ACE inhibition), a blood pressure medicine. Understanding how these drugs interact in healthy people will help us learn their potential effects in people who have diabetes.
NCT00895414 ↗	Enalapril Maleate and Doxorubicin Hydrochloride in Treating Women With Breast Cancer	Completed	Masonic Cancer Center, University of Minnesota	N/A	2009-04-01	RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Enalapril maleate may help protect heart cells from the side effects of chemotherapy. It is not yet known whether giving enalapril maleate before or after doxorubicin hydrochloride is more effective in treating women with breast cancer. PURPOSE: This randomized clinical trial is studying giving enalapril maleate together with doxorubicin hydrochloride to see how well it works in treating women with breast cancer.
NCT00741156 ↗	The Acute Effects of the Angiotensin-converting Enzyme Inhibitor Enalaprilat on Flow Distribution	Completed	The Hospital for Sick Children	Phase 3	2008-07-01	The primary objective of this study is to study the acute effects of angiotensin-converting enzyme inhibitor (ACEI) on systemic, pulmonary and cerebral blood flow in post bidirectional cavopulmonary connection (BCPC) patients.
NCT00248807 ↗	A Study of Blood Pressure and Blood Supply to the Brain in Persons With a Spinal Cord Injury.	Completed	US Department of Veterans Affairs	N/A	2005-10-01	The purpose of this study is to determine how blood pressure and blood flow are controlled during head-up tilt in a semi-upright position. In this investigation we are studying blood pressure and blood flow to the brain, with and without a medication which lowers blood pressure (Vasotec). We will determine how persons with a spinal cord injury are able to maintain blood flow to the brain (not get dizzy) as they assume a more upright position and their blood pressure decreases.
NCT00248807 ↗	A Study of Blood Pressure and Blood Supply to the Brain in Persons With a Spinal Cord Injury.	Completed	VA Office of Research and Development	N/A	2005-10-01	The purpose of this study is to determine how blood pressure and blood flow are controlled during head-up tilt in a semi-upright position. In this investigation we are studying blood pressure and blood flow to the brain, with and without a medication which lowers blood pressure (Vasotec). We will determine how persons with a spinal cord injury are able to maintain blood flow to the brain (not get dizzy) as they assume a more upright position and their blood pressure decreases.

Clinical Trial Conditions for VASOTEC

Condition Name

Condition Name for VASOTEC
Intervention	Trials
Hypertension	3
Hypotension on Induction	1
Metastatic Malignant Melanoma	1
Orthostatic Hypotension	1

Condition MeSH

Condition MeSH for VASOTEC
Intervention	Trials
Hypertension	3
Hypotension	2
Spinal Cord Injuries	1
Angioedema	1

Clinical Trial Locations for VASOTEC

Trials by Country

+

−

Trials by Country for VASOTEC
Location	Trials
United States	5
Norway	1
Canada	1

Trials by US State

+

−

Trials by US State for VASOTEC
Location	Trials
Georgia	1
Nebraska	1
Tennessee	1
Minnesota	1
New York	1

Clinical Trial Progress for VASOTEC

Clinical Trial Phase

Clinical Trial Phase for VASOTEC
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	1
Phase 2	1

Clinical Trial Status

Clinical Trial Status for VASOTEC
Clinical Trial Phase	Trials
Completed	5
Withdrawn	1
Terminated	1

Clinical Trial Sponsors for VASOTEC

Sponsor Name

Sponsor Name for VASOTEC
Sponsor	Trials
Brigham and Women's Hospital	2
The Norwegian Melanoma Group	1
Haukeland University Hospital	1

Sponsor Type

Sponsor Type for VASOTEC
Sponsor	Trials
Other	11
U.S. Fed	2
Industry	1

Vasotec (Enalapril): Clinical Trials, Market Analysis, and Projections

Introduction

Vasotec, also known as enalapril, is an angiotensin-converting enzyme (ACE) inhibitor widely used in the management of hypertension and heart failure. This article delves into recent clinical trials, market analysis, and future projections for this crucial medication.

Clinical Trials Update

Enalapril in Rheumatoid Arthritis

A clinical trial focusing on the effects of enalapril on arterial stiffness in women with rheumatoid arthritis (RA) revealed significant findings. The study involved 53 patients randomly assigned to receive either 5 mg of enalapril or a placebo twice a day. After 12 weeks, the results showed a reduction in cardiovascular ankle index (CAVI) in the enalapril group, indicating improved arterial stiffness. This trial highlights the potential benefits of enalapril in managing cardiovascular risks associated with RA[1].

PARADIGM-HF Trial

The PARADIGM-HF trial compared the efficacy of sacubitril/valsartan with enalapril in patients with heart failure due to reduced ejection fraction (EF). The trial demonstrated that sacubitril/valsartan was superior to enalapril in reducing cardiovascular death or hospitalization for heart failure. At a median of 27 months, the primary outcome occurred in 21.8% of the sacubitril/valsartan group versus 26.5% of the enalapril group. This study suggests that while enalapril is effective, newer combinations like sacubitril/valsartan may offer better outcomes in certain patient populations[4].

Mechanism of Action and Clinical Effects

Enalapril works by inhibiting the angiotensin-converting enzyme, leading to vasodilation and a reduction in cardiac workload. This mechanism results in lowered blood pressure and improved cardiac output. In patients with essential hypertension, enalapril has been shown to reduce peripheral arterial resistance and increase renal blood flow without significantly affecting heart rate[3].

Market Analysis

Global Market Size and Growth

The global enalapril market is projected to grow significantly due to the rising prevalence of cardiovascular diseases. According to Cognitive Market Research, the global enalapril market size is expected to expand at a compound annual growth rate (CAGR) of 6.20% from 2024 to 2031. The market is driven by increasing awareness of cardiovascular health, lifestyle changes, and an aging population[5].

Regional Market Dynamics

North America currently dominates the enalapril market, driven by the high prevalence of hypertension and cardiovascular diseases. The region is expected to continue its significant growth during the projected period. Asia-Pacific is also anticipated to make substantial gains, with the highest CAGR, due to rising hypertension rates and improving healthcare access[5].

Market Segments

The hypertension segment holds the largest share of the enalapril market, driven by the growing prevalence of hypertension and the emphasis on effective blood pressure control. The congestive heart failure segment is also expanding rapidly, as healthcare professionals recognize enalapril's efficacy in reducing symptoms and improving patient outcomes[5].

Market Projections

Forecast Period

From 2024 to 2031, the enalapril market is expected to see robust growth. The North American market is projected to grow at a CAGR of 4.4%, while the Asia-Pacific region is expected to grow at a CAGR of 8.2%. Europe and Latin America will also experience significant growth, with CAGRs of 4.7% and 5.6%, respectively[5].

Key Drivers

The market growth is driven by several factors, including:

• Increasing Prevalence of Cardiovascular Diseases: The rising number of patients with hypertension and heart failure is a major driver.
• Improving Healthcare Infrastructure: Better diagnosis and treatment access are fueling market expansion.
• Aging Population: The growing older population contributes to increased diagnoses and treatments.
• Research and Development: Ongoing R&D efforts are introducing novel ACE inhibitors with enhanced efficacy and reduced side effects[2][5].

Competitive Landscape

ACE Inhibitors Market

The ACE inhibitors market, of which enalapril is a part, is a significant segment within the pharmaceutical industry. The market is valued at USD 2.18 billion in 2023 and is anticipated to reach USD 2.93 billion by 2029, growing at a CAGR of 5.25%. The widespread adoption of ACE inhibitors as first-line treatments for cardiovascular conditions continues to drive market growth[2].

Conclusion

Enalapril, marketed as Vasotec, remains a crucial medication in the management of hypertension and heart failure. Recent clinical trials highlight its efficacy and potential benefits in various patient populations. The market for enalapril is expected to grow significantly, driven by the increasing prevalence of cardiovascular diseases, improving healthcare infrastructure, and ongoing research and development.

Key Takeaways

• Clinical Efficacy: Enalapril reduces arterial stiffness and improves cardiovascular outcomes.
• Market Growth: The global enalapril market is projected to grow at a CAGR of 6.20% from 2024 to 2031.
• Regional Dynamics: North America and Asia-Pacific are key regions driving market growth.
• Market Drivers: Increasing prevalence of cardiovascular diseases, improving healthcare infrastructure, and an aging population are major drivers.
• Competitive Landscape: The ACE inhibitors market is valued at USD 2.18 billion in 2023 and is expected to reach USD 2.93 billion by 2029.

FAQs

What is the primary mechanism of action of enalapril?

Enalapril works by inhibiting the angiotensin-converting enzyme, leading to vasodilation and a reduction in cardiac workload.

How does the PARADIGM-HF trial impact the use of enalapril?

The PARADIGM-HF trial showed that sacubitril/valsartan was superior to enalapril in patients with heart failure due to reduced ejection fraction, suggesting that newer combinations may offer better outcomes in certain patient populations.

What are the key drivers of the enalapril market growth?

The key drivers include the increasing prevalence of cardiovascular diseases, improving healthcare infrastructure, an aging population, and ongoing research and development.

Which regions are expected to drive the growth of the enalapril market?

North America and Asia-Pacific are expected to be the key regions driving market growth.

What is the projected CAGR for the global enalapril market from 2024 to 2031?

The global enalapril market is expected to grow at a CAGR of 6.20% from 2024 to 2031.

Sources

1. Frontiers in Medicine: Enalapril Influence on Arterial Stiffness in Rheumatoid Arthritis Women.
2. TechSci Research: North America ACE Inhibitors Market By Size, Share and Forecast.
3. FDA: tablets vasotec® (enalapril maleate).
4. American College of Cardiology: Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure - PARADIGM-HF.
5. Cognitive Market Research: Global Enalapril Market Report.